Upgrade to SI Premium - Free Trial

Quantum BioPharma (QNTM)

3.46 +0.26 (8.12%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26 *Est.)

Latest Headlines

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research September 14, 2026 8:30 AM - StreetInsider Quantum BioPharma gets FDA clearance for MS drug phase 2 trial September 11, 2026 8:31 AM - StreetInsider Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials September 11, 2026 8:30 AM - Globe NewsWire Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials September 11, 2026 8:30 AM - StreetInsider Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market September 10, 2026 8:30 AM - StreetInsider Quantum BioPharma gets FDA clearance for MS drug trial September 9, 2026 8:32 AM - StreetInsider Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment September 9, 2026 8:30 AM - StreetInsider A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach September 8, 2026 8:30 AM - StreetInsider Rodman & Renshaw Starts (QNTM) at Buy August 31, 2026 7:03 AM - StreetInsider Form 6-K Quantum Biopharma Ltd. For: Aug 14 August 14, 2026 7:00 AM - SEC Filing Quantum BioPharma gets FDA nod for Lucid-MS Phase 2 MS trial August 14, 2026 7:00 AM - StreetInsider Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial August 14, 2026 7:00 AM - StreetInsider Form 6-K Quantum Biopharma Ltd. For: Jun 30 August 13, 2026 4:08 PM - SEC Filing Form 6-K/A Quantum Biopharma Ltd. For: Aug 13 August 13, 2026 11:07 AM - SEC Filing Form 6-K Quantum Biopharma Ltd. For: Aug 10 August 10, 2026 7:00 AM - SEC Filing Quantum BioPharma gets FDA clearance for Lucid-MS phase 2 MS trial August 10, 2026 7:00 AM - StreetInsider Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis: August 10, 2026 7:00 AM - StreetInsider Form SCHEDULE 13G Quantum Biopharma Ltd. Filed by: AdvisorShares Trust July 8, 2026 5:21 PM - SEC Filing NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis June 26, 2026 8:30 AM - StreetInsider Quantum BioPharma MS drug candidate moves toward phase 2 trials June 25, 2026 8:32 AM - StreetInsider Quantum BioPharma MS drug candidate nears phase 2 trials June 25, 2026 8:31 AM - StreetInsider Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy June 25, 2026 8:30 AM - Globe NewsWire Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy June 25, 2026 8:30 AM - StreetInsider The Quest to Repair What Multiple Sclerosis Takes Away June 24, 2026 8:30 AM - StreetInsider Quantum BioPharma's MS drug candidate nears phase 2 trials June 23, 2026 8:31 AM - StreetInsider Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach June 23, 2026 8:30 AM - StreetInsider Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis June 22, 2026 8:30 AM - StreetInsider Full Article List